{"id":10457,"date":"2026-06-25T16:59:55","date_gmt":"2026-06-25T08:59:55","guid":{"rendered":"https:\/\/www.excelsiormedical.com.tw\/?p=10457"},"modified":"2026-06-29T09:53:27","modified_gmt":"2026-06-29T01:53:27","slug":"the-2026-annual-shareholders-meeting-passes-to-release-the-prohibition-on-directors-from-participation-in-competition-businesses","status":"publish","type":"post","link":"https:\/\/www.excelsiormedical.com.tw\/en\/investors\/the-2026-annual-shareholders-meeting-passes-to-release-the-prohibition-on-directors-from-participation-in-competition-businesses\/","title":{"rendered":"The 2026 Annual Shareholders’ Meeting passes to release the prohibition on directors from participation in competition businesses."},"content":{"rendered":"

 <\/p>\n\n\n\n\n\n\n
SEQ_NO<\/td>\n\u00a02<\/td>\nDate of announcement<\/td>\n2026\/06\/25<\/td>\nTime of announcement<\/td>\n16:59:03<\/td>\n<\/tr>\n
Subject<\/td>\n\n
The 2026 Annual Shareholders' Meeting passes to release the prohibition on directors from participation in competition businesses.<\/pre>\n<\/td>\n<\/tr>\n
Date of events<\/td>\n2026\/06\/25<\/td>\nTo which item it meets<\/td>\nparagraph 21<\/td>\n<\/tr>\n
Statement<\/td>\n\n
1.Date of the shareholders meeting resolution:2026\/06\/25\r\n2.Name and title of the director with permission to engage in competitive conduct:\r\nDirector:Excelsior Group Holdings Co., Ltd. Representative:Chen Tun-Ling\r\nDirector:Excelsior Group Holdings Co., Ltd. Representative:Chang Hsien-Cheng\r\nDirector:Chang Ming-Cheng\r\nDirector:Fu Jo-Hsuan\u78ba\u5b9a<\/a>\r\nIndependent director:Kuo,Ming-Yi\r\n3.Items of competitive conduct in which the director is permitted to engage:\r\nConcurrently serve as a director with the same or similar business scope as the Company.\r\n4.Period of permission to engage in the competitive conduct:\r\nA director's term of office.\r\n5.Circumstances of the resolution (please describe the results of voting in accordance with Article 209 of the Company Act):\r\nThe resolution was adopted by a majority of the shareholders presented at the general meeting who represented two-thirds or more of the total number\r\nof shares represented by the attending shareholders.\r\n6.If the permitted competitive conduct belongs to the operator of a mainland China area enterprise, the name and title of the directors\r\n(if it is not the operator of a Mainland-area enterprise, please enter \u201cN\/A\u201d below):Not Applicable.\r\n7.Company name of the mainland China area enterprise and the director's position in the enterprise:Not Applicable.\r\n8.Address of the mainland China area enterprise:Not Applicable.\r\n9.Operations of the mainland China area enterprise:Not Applicable.\r\n10.Impact on the company's finance and business:None.\r\n11.If the directors have invested in the mainland China area enterprise, the monetary amount of the investment and their shareholding ratio:None.\r\n12.Any other matters that need to be specified:None.\r\n<\/pre>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n","protected":false},"excerpt":{"rendered":"
  SEQ_NO \u00a02 Date of announcement 2026\/06\/25 Time of announcement 16:59:03 Subject The 2026 Annual Shareholders’ Meeting passes to release the prohibition on directors from participation in competition businesses. Date of events 2026\/06\/25 To which item it meets paragraph 21 Statement 1.Date of the shareholders meeting resolution:2026\/06\/25 2.Name and title of the director with permission …<\/p>\n
  The 2026 Annual Shareholders’ Meeting passes to release the prohibition on directors from participation in competition businesses.<\/span> Read More »<\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"default","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","footnotes":"","_links_to":"","_links_to_target":""},"categories":[72,102],"tags":[],"class_list":["post-10457","post","type-post","status-publish","format-standard","hentry","category-investors","category-material-information"],"_links":{"self":[{"href":"https:\/\/www.excelsiormedical.com.tw\/en\/wp-json\/wp\/v2\/posts\/10457","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.excelsiormedical.com.tw\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.excelsiormedical.com.tw\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.excelsiormedical.com.tw\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.excelsiormedical.com.tw\/en\/wp-json\/wp\/v2\/comments?post=10457"}],"version-history":[{"count":2,"href":"https:\/\/www.excelsiormedical.com.tw\/en\/wp-json\/wp\/v2\/posts\/10457\/revisions"}],"predecessor-version":[{"id":10459,"href":"https:\/\/www.excelsiormedical.com.tw\/en\/wp-json\/wp\/v2\/posts\/10457\/revisions\/10459"}],"wp:attachment":[{"href":"https:\/\/www.excelsiormedical.com.tw\/en\/wp-json\/wp\/v2\/media?parent=10457"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.excelsiormedical.com.tw\/en\/wp-json\/wp\/v2\/categories?post=10457"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.excelsiormedical.com.tw\/en\/wp-json\/wp\/v2\/tags?post=10457"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}